Literature DB >> 25872113

Opioid-induced hyperalgesia: where are we now?

Kirsty Bannister1.   

Abstract

PURPOSE OF REVIEW: Patients receiving chronic opioid treatment who develop paradoxical pain sensations, as well as worsening existing pain, can be diagnosed as suffering from opioid-induced hyperalgesia (OIH). As the worldwide population expands so too does the proportion of patients who experience pain that requires a strong opioid. Recognizing the symptoms of OIH and optimizing the use of morphine in the hospital setting is imperative. This review focuses on clinical data relating to evidence of OIH at the bedside and the novel techniques employed by healthcare providers in order to improve the heightened pain sensations experienced by susceptible patients. RECENT
FINDINGS: An increasing number of randomized prospective controlled trials report worsening patient pain following high-dose opioid treatment. Patient case reports support the premise that OIH is a clinical reality. According to recent literature, for those individuals who develop paradoxical pain sensations upon chronic opioid therapy, the most successful course of action involves a multidisciplinary attack that usually comprises early diagnosis, opioid switching and adjunct therapies.
SUMMARY: Looking to the future, improved clinician-patient communication, advanced diagnostic techniques and a refinement of prescribed adjunct pharmacotherapies will offer the most successful multimodal pain management approach to the problem of OIH.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25872113     DOI: 10.1097/SPC.0000000000000137

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  11 in total

Review 1.  Opioids and Chronic Pain: Where Is the Balance?

Authors:  Mellar P Davis; Zankhana Mehta
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

2.  Automated Mobile Phone Messaging Utilizing a Cognitive Behavioral Intervention: A Pilot Investigation.

Authors:  Edward O Rojas; Chris A Anthony; Jill Kain; Natalie Glass; Apurva S Shah; Tammy Smith; Benjamin J Miller
Journal:  Iowa Orthop J       Date:  2019

Review 3.  Optimizing the management of chronic pain in sickle cell disease.

Authors:  Ifeyinwa Osunkwo; Hazel F O'Connor; Elna Saah
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

4.  Implementation of an Opioid Stewardship Program to Promote Safer Opioid Prescribing.

Authors:  Lianping Ti; Tamara Mihic; Hannah James; Stephen Shalansky; Michael Legal; Seonaid Nolan
Journal:  Can J Hosp Pharm       Date:  2022-04-04

5.  Divergent profiles of fentanyl withdrawal and associated pain in mice and rats.

Authors:  Olivia Uddin; Carleigh Jenne; Megan E Fox; Keiko Arakawa; Asaf Keller; Nathan Cramer
Journal:  Pharmacol Biochem Behav       Date:  2020-12-11       Impact factor: 3.533

6.  Anti-nerve growth factor antibody attenuates chronic morphine treatment-induced tolerance in the rat.

Authors:  Bopaiah P Cheppudira; Alex V Trevino; Lawrence N Petz; Robert J Christy; John L Clifford
Journal:  BMC Anesthesiol       Date:  2016-09-05       Impact factor: 2.217

7.  Monocyte chemoattractant protein-1 contributes to morphine tolerance in rats with cancer-induced bone pain.

Authors:  Lei Liu; Xiu-Juan Gao; Chun-Guang Ren; Ji-Hua Hu; Xian-Wen Liu; Ping Zhang; Zong-Wang Zhang; Zhi-Jian Fu
Journal:  Exp Ther Med       Date:  2016-12-16       Impact factor: 2.447

8.  Association of morphine-induced analgesic tolerance with changes in gene expression of GluN1 and MOR1 in rat spinal cord and midbrain.

Authors:  Shamseddin Ahmadi; Fatemeh Miraki; Jalal Rostamzadeh
Journal:  Iran J Basic Med Sci       Date:  2016-09       Impact factor: 2.699

9.  Pancreatic QST Differentiates Chronic Pancreatitis Patients into Distinct Pain Phenotypes Independent of Psychiatric Comorbidities.

Authors:  Mahya Faghih; Anna E Phillips; Louise Kuhlmann; Elham Afghani; Asbjørn M Drewes; Dhiraj Yadav; Vikesh K Singh; Søren S Olesen
Journal:  Clin Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 11.382

10.  Withdrawal-associated injury site pain (WISP): a descriptive case series of an opioid cessation phenomenon.

Authors:  Launette Marie Rieb; Wendy V Norman; Ruth Elwood Martin; Jonathan Berkowitz; Evan Wood; Ryan McNeil; M-J Milloy
Journal:  Pain       Date:  2016-12       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.